rorγt inverse agonist 3

RORγt Inverse Agonist 3 is a potent, selective, and orally active inverse agonist of RORγ with EC50 values of 0.22 μM for hRORγ and 0.15 μM for RORγt (human IL-17 cells), respectively.

GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50 value of 1.4 μg in the β-arrestin recruitment assay.GPR35 agonist 3 is used in the study of cancer, type 2 diabetes, and cardiovascular disease.

CB1 inverse agonist 1 (MRL-650) is an orally active and selective CB1 agonist. The IC50s for CB1 and CB2 are 7.5 nM and 4100 nM, respectively. CB1 inverse agonist 1 shows anorexigenic effects.

RORγt inverse agonist 13 (Compound 3i) is a potent, orally active, and selective inverse agonist for RORγt with an IC50 of 63.8 nM, exhibiting improved drug-like properties[1].

TLR7 8 agonist 3 is a potent activator of TLR7 and TLR8.

RORγt Inverse agonist 6 is an agonist of RORγt inverse. RORγt Inverse agonist 6 can be used in research on Th17-driven autoimmune diseases.

GPR120 Agonist 3 (GPR120-IN-1) is a selective agonist of Gpr120 ( logEC50: -7.62).

RORγt inverse agonist 31 (14g) is a potent antagonist of the retinoic acid receptor-related orphan receptor γt (RORγt), with an inhibitory concentration (IC50) of 0.428 μM. It has shown efficacy in reducing Imiquimod-induced psoriasis severity in murine models [1].

Nurr1 Inverse Agonist-1 is an inverse agonist for the neuroprotective transcription factor Nurr1, serving as a research tool.

Compound 1, identified as a GPR61 inverse agonist, exhibits an IC50 of 11 nM, rendering it suitable for metabolism and body weight disorder research, including obesity and cachexia [1].

Ir[p-F(t-Bu)-ppy]3 is a useful organic compound for research related to life sciences and the catalog number is T64556.

1-(t-Boc-Aminooxy)-3-aminooxy-propane is an alkyl ether-based PROTAC linker used in the synthesis of PROTACs [1].

PPARγ agonist 3, also known as Compound 18a, is a potent and selective agonist of PPARγ. This compound does not exhibit cytotoxicity towards both non-resistant and resistant cells. Notably, PPARγ agonist 3 demonstrates antitumor efficacy exclusively when co-administered with Imatinib [1].

3'-O-t-Butyldimethylsilyl adenosine is a Nucleoside; Used for special nucleoside modification.

GLP-1 receptor agonist 3 is a GLP-1 receptor agonist,Example 4A-1, has EC50s of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell lines assay, respectively.

Nucleoside Derivatives - 5-Modified pyrimidine nucleosides, Protected nucleosides with NH2/OH open

TGR5 Receptor Agonist 3 is a G protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonist soft drug compound that decreases gallbladder filling, exhibits good gallbladder safety, and is able to act on hTGR5 (EC50: 16.4 nM) and mTGR5 (EC50: 209 nM).

3'-O-(t-Butyldiphenylsilyl)thymidine is a Nucleoside Derivative - Protected nucleoside w/NH2/OH open.

RORγt inverse agonist 30 (Compound 1) is a potent RORγt inverse agonist with an IC50 of 46 nM, making it effective in the treatment of autoimmune diseases by targeting the nuclear receptor RORγt.

(2S,3S)-N-t-Boc-3-amino-1,2-epoxy-4-phenylbutane is a useful organic compound for research related to life sciences. The catalog number is T66307 and the CAS number is 98737-29-2.

AHR agonist 3 is an agent with therapeutic activity.

RORγ inverse agonist 1 has anti-inflammatory activity and can be used to treat rheumatism and psoriasis.

Methanesulfonato(tri-t-butylphosphino)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) is a useful organic compound for research related to life sciences and the catalog number is T67261.

2',3'-Bis-O-(t-butyldimethylsilyl)-5'-O-(4,4'-dimethyltriphenylmethyl)uridine is a nucleoside Derivative - Other modified nucleoside.

4'-alpha-C-Allyl-2',3'-bis(O-t-butyldimethylsilyl)uridine is a Nucleoside Derivative - 4'-Modified nucleoside; Protected nucleoside w/NH2/OH open.

RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist (human RORγt-LBD) with an IC50 of 19 nM.

3'-O-(t-Butyldimethylsilyl)-2'-deoxyadenosine is a Nucleoside Derivative - Protected nucleoside with NH2/OH group open.

RORγt inverse agonist 28 is a potent RORγt inverse agonist that regulates the differentiation of Th17 cells and inhibits IL-17 production, showing research potential in inflammatory and autoimmune diseases.

5-HT2A receptor agonist-3 represents the highest selectivity for the human 5-HT2A receptor currently identified, exhibiting a K i of 2.5 nM. It also demonstrates a remarkable 124-fold selectivity over its structurally analogous 5-HT2C receptor [1].

Compound CMC23, an FPR2 agonist, mitigates lactate dehydrogenase release in LPS-stimulated cultures and reduces pro-inflammatory IL-1β and IL-6 levels. It also attenuates phosphor-STAT3 levels through the STAT3/SOCS3 signaling pathway [1].

Nucleoside Derivative –4’-Modified nucleosides; Protected nucleosides with NH2/OH group

Nucleosides - 2’-deoxynucleoside

N4-Benzoyl-2',3'-di-O-(t-butyldimethylsilyl)-5'-O-(4,4'-dimethoxytrityl)-N4-methylcytidine is a nucleoside Derivative - Other modified nucleoside.

2’,3’-Bis-O-(t-butyldimethylsilyl)-N1-methylpseudouridine, catalog number TNU1576, is a valuable organic compound for life sciences research.

CB1 Inverse Agonist 2, an orally active compound, serves as an inverse agonist for the Cannabinoid Receptor CB1. It effectively counteracts the hypothermia and anorexia induced by CP55940 in mouse models.

Glucocorticoid Receptor Agonist-3 (Preparation 6) acts as a glucocorticoid receptor agonist [1].

Compound A229 (PPARα agonist3) is a PPARα agonist (EC50: 590 nM) that inhibits the generation of reactive oxygen species induced by TBHP or 4-HNE.

Compound 15A, also known as A3AR agonist 3, acts as an agonist for the A3 adenosine receptor (A3AR), exhibiting K_i and EC_50 values of 2.27 nM and 0.20 nM for hA3 and cAMP, respectively. This compound is utilized in neuroinflammation research [1].

DOTA-(t-butyl)3-PEG5-azide is a polyethylene glycol (PEG)-derived linker specifically designed for the synthesis of proteolysis targeting chimeras (PROTACs)[1].

Wnt/β-catenin agonist 3 is a Wnt/beta-catenin agonist.

Nucleoside Derivatives - Thio-nucleosides, Protected nucleosides with NH2/OH open

FXR agonist 3 is an anti-NASH compound with antifibrotic and anti-fibrotic activity, inhibiting the expression of COL1A1, TGF-β1, α-SMA, and TIMP1, with an IC50 value of 8.19 μmol L for COL1A1. FXR agonist 3 ameliorates CDAHFD and BDL-induced liver injury in vivo by activating FXR.

THR-β agonist 3 is a potent agonist of THR-β with demonstrated research potential for metabolic diseases, including obesity, hyperlipidemia, hypercholesterolemia, diabetes, steatosis, non-alcoholic steatohepatitis (NASH), and atherosclerosis.

5-HT2C agonist-3 ((+)-19) free base is a selective 5-HT2C agonist (EC50: 24 nM, Ki: 78 nM) that exhibits antipsychotic drug-like activity and inhibits Amphetamine-induced hyperactivity [1].

N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine is a nucleoside derivative categorized as a C-nucleoside and an N-alkylated nucleoside.

STING agonist-3 trihydrochloride is a selective and non-nucleotide agonist of small-molecule STING(pEC50 and pEC50 of 7.5 and 9.5, respectively), has durable anti-tumor effect and tremendous potential to improve treatment of cancer.

MRGPRX1 agonist 3 (compound 1f) is a potent positive allosteric modulator of Mas-related G protein-coupled receptor X1 (MRGPRX1) with an EC50 of 0.22 μM, and it can be used for neuropathic pain research[1].

GP 2A is a selective agonist of CB2 receptor.